ArticleRespiratory research2025
Immunological landscape of children with Mycoplasma pneumoniae pneumonia in the post-COVID-19 era reveals distinctive severity indicators.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- High-Dimensional Immune Profiling Reveals Innate-Adaptive Rebalancing and Subpopulation Trajectories in Pediatric SevereDiagnostics (Basel, Switzerland) · 2026Article
- Serum IL-6, IL-8, and Th/Ts ratio for severity assessment and short-term clinical outcome risk stratification in pediatric Mycoplasma pneumoniae pneumonia: insights into inflammation-immune imbalance.European journal of pediatrics · 2026Article
- Impact of Allergic Diseases or Obstructive Sleep Apnea Risk on SevereJournal of clinical medicine · 2026Article
- Epidemiological dynamics of respiratory tract infections in a major northern coastal city (Dalian), China, following the COVID-19 pandemic.BMC infectious diseases · 2026Article
- Impact of early corticosteroid therapy on short-term pulmonary function and clinical outcomes in children with severeFrontiers in pediatrics · 2026Article
- A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.Frontiers in immunology · 2026Article
- Immune dysregulation and pathogen prevalence in Mycoplasma pneumoniae pneumonia: a retrospective insight in children.Frontiers in pediatrics · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Machine learning-driven risk assessment of severeFrontiers in medicine · 2026Article
- Inflammatory Mediation of the Association Between Latent Clinical Phenotypes and Multidimensional Outcomes in Pediatric Community-Acquired Pneumonia.Journal of inflammation research · 2026Article
- Research Progress on Point-of-Care Testing Technology for Mycoplasma Pneumonia.International journal of general medicine · 2026Review
- A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic era.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Development and validation of a CD4+/CD8+ ratio-based nomogram to predict plastic bronchitis in pediatricFrontiers in pediatrics · 2025Article
- High-altitude immune remodeling in children withFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundThere is a recent global surge in Mycoplasma pneumoniae pneumonia (MPP). However, the key immune factors that contribute to the advancement of the disease remain unknown. Hence, we conducted this study to uncover the immunological profile in children affected by MPP.
methodsThis study enrolled children visiting Children's Hospital of Fudan University from December 2023 to April 2024, including 34 healthy controls, 51 severe MPP (S-MPP), 27 non-severe MPP (NS-MPP), and 34 non-MPP pneumonia (NMP) cases. Their blood samples were analyzed using flow cytometry, multi-cytokine assays, and antibody detection methods.
resultsCompared with NMP cases, MPP cases displayed higher frequencies of natural killer T cells, classical monocytes, and monocytic myeloid-derived suppressor cells. Notably, both T helper type 1 and activated regulatory T cells were more abundant in MPP cases, particularly in S-MPP, whereas CD8 + T cells displayed an exhaustion phenotype. The proportion of naïve B cells was reduced, while functional B cells, including memory B cells and plasmablasts, increased in S-MPP. 12 out of 95 clinical laboratory indicators and 3 out of 48 cytokines significantly differed between S-MPP and NS-MPP. Finally, we performed logistic and LASSO regression analyses and developed a predictive model for S-MPP that incorporates naïve B cell percentage from flow cytometry, cholinesterase from clinical laboratory tests, and interleukin 18 from the cytokine assay.
conclusionsThese results clarify the immunological features in pediatric MPP cases, and identify novel markers for severe cases, providing insights for early diagnosis and immunological management in affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.